With over 30 years of experience in drug device engineering, Antares Pharma has nurtured its R&D prowess and specialized in creating custom designed drug delivery devices that are tailored to the ...
Study met primary end point and demonstrated successful subcutaneous administration of a 10 mL biologic co-formulated with ENHANZE® in 30 seconds using Halozyme's proprietary high-volume auto-injector ...
Please provide your email address to receive an email when new articles are posted on . Psoriasis patients who self-administer bimekizumab experienced similar levels of comfort and success with both ...
Together, Ram and Carrie strengthen Kaléo’s leadership team as the Company continues to support its autoinjector portfolio, advance development programs aligned with emergency preparedness, and ...
DETROIT & BOSTON, December 04, 2025--(BUSINESS WIRE)--Sempresto, Inc., a medical device company pioneering smartphone integrated rescue drug delivery, today announced the acquisition of Alerje’s ...
EWING, N.J., Aug. 16, 2018 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“Antares”) today announced that the U.S. Food and Drug Administration (FDA ...
Let us help you with your inquiries, brochures and pricing requirements Request A Quote Download PDF Copy Request A Quote Download PDF Copy Request A Quote Download ...
Study met primary end point and demonstrated successful subcutaneous administration of a 10 mL biologic co-formulated with ENHANZE® in 30 seconds using Halozyme's proprietary high-volume auto-injector ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results